For veterans working in the cleared national security community, “alternative” mental health treatment has long carried an additional question that most Americans never have to consider: what could this mean for my security clearance?
That question may become increasingly complicated as the Department of Veterans Affairs moves deeper into psychedelic-assisted mental health research.
The VA announced in August that it is launching a major clinical trial examining psilocybin as a potential treatment for veterans with treatment-resistant major depression, including veterans who also have post-traumatic stress disorder.
The study, called Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression, or PIVOT, represents another significant step toward bringing psychedelic research into mainstream veteran health care.
For veterans who have cycled through medications, therapy, and other treatments without meaningful improvement, that research could eventually open another door. For veterans holding security clearances, however, it also raises some unusual questions.
The VA Is Taking Psychedelics Seriously
This isn’t the VA suddenly deciding to hand veterans psychedelic mushrooms. PIVOT is a controlled clinical trial designed to determine whether psilocybin can safely and effectively help veterans whose depression has not responded to existing treatments.
The study is expected to include roughly 240 veterans and operate at five VA medical centers: Birmingham and Tuscaloosa, Alabama; Philadelphia; Portland, Oregon; and the VA Puget Sound Health Care System in Washington.
Participants will receive pharmaceutical-grade psilocybin or a comparator under controlled conditions with therapeutic support, with researchers evaluating changes in depression symptoms, PTSD severity, side effects, and patient-reported outcomes.
The study is also part of a greater effort. VA researchers are now involved in numerous clinical trials examining psychedelic substances for mental health conditions. The department has also expanded research involving MDMA-assisted therapy. For a veteran population that experiences significant rates of PTSD, depression, and other mental health challenges, the willingness to explore additional treatment options matters. But there is an elephant in the room for the cleared workforce.
Psilocybin Is Still Federally Illegal
Despite growing medical research and changes to psychedelic regulation in some jurisdictions, psilocybin remains a Schedule I controlled substance under federal law. That distinction matters to anyone holding or pursuing a security clearance. Other Schedule I substances include heroin, LSD, marijuana, and bath salts.
Drug involvement and substance misuse are considered under Guideline H of the National Security Adjudicative Guidelines. Illegal drug use, particularly while holding a clearance, can raise concerns regarding judgment, reliability, and willingness to comply with federal law.
That has created familiar problems for cleared workers when it comes to marijuana. A substance may be legal under state law, socially accepted, and even recommended for medical purposes in some jurisdictions while remaining prohibited under federal law.
Psilocybin could eventually create a similar divide. There is, however, an enormous difference between taking psychedelic drugs on your own and receiving a controlled substance as part of an authorized federal clinical trial.
A VA Trial Is Not Self-Medication
This distinction may be the most important takeaway for cleared veterans reading about the PIVOT trial. The VA is not encouraging veterans to obtain psilocybin independently. The department has specifically warned veterans against self-medicating with psychedelics or replacing established mental health treatment with unprescribed substances.
VA psychedelic research is being conducted in controlled clinical environments under federal research and safety protocols.
This makes a big difference when it comes to security-clearance adjudications, which use the whole-person concept. Adjudicators examine circumstances surrounding conduct rather than making every decision based on a single fact in isolation. Participation in an authorized VA clinical trial should therefore not be confused with recreational or unauthorized psilocybin use.
Still, cleared veterans considering participation would be wise to understand any reporting requirements that apply to their specific agency, position, or security program before enrolling. That is particularly important because psychedelic medicine is moving faster than many workplace policies were designed to accommodate.
Mental Health Treatment Is Changing
There is another reason the cleared community should pay attention to PIVOT. The national security workforce contains a substantial veteran population. Many of those veterans carried experiences from Iraq, Afghanistan, and other deployments directly into careers across the intelligence community, defense contracting, cybersecurity, federal law enforcement, and the broader national security apparatus.
Some veterans are also living with depression or PTSD that has resisted conventional treatment. And for decades, the conversation surrounding mental health and security clearances has gradually shifted away from the idea that seeking treatment itself demonstrates unreliability. Psychedelic-assisted therapy could become the next test of that evolution.
If research eventually demonstrates that substances such as psilocybin can safely treat certain mental health conditions, federal agencies may eventually have to reconcile medical innovation with personnel security policies built around substances that remain federally controlled.
That doesn’t mean the rules have changed today. They haven’t, and they probably won’t for a long time. Psilocybin remains federally controlled, and cleared workers should not interpret VA research as permission to experiment with psychedelic drugs independently. However, the federal government studying these substances in veterans represents a meaningful shift.
This Could Become a Clearance Question
The PIVOT trial is not a typical medical study. It sits at the intersection of three communities that overlap heavily: veterans, mental health care and the cleared national security workforce. For veterans who have exhausted traditional treatments, psychedelic research may eventually provide another option.
- For the clearance community, it raises questions that policymakers, security managers, and adjudicators may increasingly have to answer.
- What happens if psychedelic-assisted therapy eventually receives FDA approval?
- How would prescribed psychedelic treatments interact with Guideline H?
- What reporting requirements would apply?
- How should the government distinguish legitimate medical treatment from illegal drug use?
Those questions may sound hypothetical today. But with the VA itself helping conduct the research, they may not remain hypothetical for very long.
